Transport molecules using reverse sequence HIV-Tat polypeptides: Not just any old Tat? (WO200808225)

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 9, 2009, Pages 1329-1333

  Howl, John ^a   Jones, Sarah ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Botulinum toxin; Cell penetrating peptide; Drug delivery; HIV 1 transactivator protein; Protein transduction domain; Skin

Indexed keywords

BOTULINUM TOXIN; CELL PENETRATING PEPTIDE; NEURONOX; PROTEIN P53; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BOTULINUM TOXIN TYPE A; CATIONS; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; PATENTS AS TOPIC; PEPTIDES; PROTEIN TRANSPORT; SKIN ABSORPTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 69949163227     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/17530050902824829     Document Type: Review

References (39)

1. Chang HC, Samaniego F, Nair BC, et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997;11:1421-1431 (Pubitemid 27421173)
2. Liu Y, Jones M, Hingtgen CM. Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000;6:1380-1387 (Pubitemid 32001023)
3. Abes S, Richard JP, Thierry A, et al. Tat-derived cell-penetrating peptides: discovery, mechanism of cell uptake, and applications to the delivery of oligonucleotides. In: Langel Ü, editor, Handbook of Cell-penetrating Peptides. CRC Press, Boca Raton, 2007. p. 29-42 • A comprehensive and historical review of the development and applications of Tat-derived CPPs.
4. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-668 • The first report that a Tat-derived peptide can deliver a large protein into several tissue types. (Pubitemid 24041462)
5. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017 • Identification of a decapeptide derived from the basic domain of Tat (Tat48-57, GRKKRRQRRR) that is a prototypic CPP. The reverse sequence of Tat49-57 is the CPP described in this patent. (Pubitemid 27265584)
6. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;76:5836-5840 •• This paper convincingly demonstrates that many arginine-rich peptides have the capacity to serve as intracellular delivery vectors. (Pubitemid 37385738)
7. Pooga M, HÄllbrink M, Zorko M, et al. Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;76:5836-5840 (Pubitemid 37385738)
8. Soomets U, Lindgren M, Gallet X, et al. Deletion analogs of transportan. Biochim Biophys Acta 2000;467:165-176
9. Jones S, Martel C, Belzacq-Casagrande AS, et al. Mitoparan and target-selective chimeric analogues: Membrane translocation and intracellular redistribution induces mitochondrial apoptosis. Biochim Biophys Acta 2008;783:849-863
10. Oehlke J, Wiesner B, Bienert M. Model amphipathic peptides. In: Langel Ü, editor, Handbook of cell-penetrating peptides. CRC Press, Boca Raton, 2007;pp. 43-60
11. Dupont E, Prochiantz A, Joliot A. Penetratins. In: Langel Ü, editor, Handbook of cell-penetrating peptides. CRC Press, Boca Raton, 2007. p. 5-28 • A scholarly review of the biology, biochemistry and applications of CPPs derived from the Antennapedia homeoprotein homeodomain that are now termed penetratins.
12. Hällbrink M, Kilk K, Elmquist A, et al. Prediction of Cell-Penetrating Peptides. Int J Pept Res Ther 2005;11:249-259
13. Hansen M, Kilk K, Langel Ü. Predicting cell-penetrating peptides. Adv Drug Deliver Rev 2008;60:572-579
14. Howl J, Jones S. Proteomimetic cell penetrating peptides. Int J Pept Res Ther 2008;14:359-366
15. Wagstaff KM, Jans DA. Protein transduction: Cell penetrating peptides and their therapeutic applications. Curr Med Chem 2006;13:1371-1387
16. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliver Rev 2005;57:579-596 • This is an extensive review of therapeutic strategies employing Tat-derived transduction vectors.
17. Abes S, Turner JT, Ivanova GD, et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 2007;35:4495-4502 (Pubitemid 47244600)
18. Coupade C, Fittipaldi A, Chagnas V, et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J 2005;390:407-418 (Pubitemid 41337102)
19. McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide- induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006;13:1373-1381 (Pubitemid 44420632)
20. Morris MC, Depollier J, Mery J, et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001;19:1173-1176 (Pubitemid 33115705)
21. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliver Rev 2008;60:530-536
22. Torchlin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Drug Deliver Rev 2008;60:548-558 (Pubitemid 351215572)
23. Chan WC, White PD. Fmoc solid phase peptide synthesis. A practical approach. Oxford University Press, New York, 2000
24. Chorev M, Goodman M. Recent developments in retro peptides and proteins - an ongoing topochemical explanation. Trends Biotechnol 1995;13:438-445
25. Chorev M, Goodman M. A dozen years of retro-inverso peptidomimetics. Acc. Chem Res 1993;26:266-273
26. Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK. Novel blockers of β-cell death. Diabetes 2001;50:77-82
27. Repici M, Centeno C, Tomasi S, et al. Time-course of c-Jun and N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 and c-Jun and caspase-3 activation. Neurosci 2007;150:40-49 •• This study indicates that RI-Tat, administered by i.p. injection, can deliver therapeutic macromolecules to brain cortical neurons. (Pubitemid 350198685)
28. Snyder EL, Meade BR, Saenz CC, et al. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:186-193 •• This report convincingly demonstrates that Tat-peptide-mediated delivery is a viable strategy for the in vivo therapeutic delivery of tumour suppressors to malignant cells.
29. Schorderet DF, Allèves V, Canola K, et al. D-TAT transporter as an ocular peptide delivery system. Clin Exp Ophthalmol 2005;33:628-635 (Pubitemid 43918404)
30. Wan L, Zhang X, Gunaseelan S, et al. Novel multi-component nanopharmaceutical derived from poly(ethylene)glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res Ther 2006;3:12 (Pubitemid 44336315)
31. Derossi D, Calvet S, Trembleau A, et al. Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. J Biol Chem 1996;271:18188-18193 (Pubitemid 26250811)
32. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-590 • This article provides substantial evidence that the translocation of Tat peptides across biological membranes is predominantly mediated by endocytotic events. (Pubitemid 36043612)
33. Suzuki T, Futaki S, Niwa M, et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002;277:2437-2443 (Pubitemid 34953265)
34. Duchardt F, Fotin-Mleczek M, Schwarz H, et al. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007;8:848-866 (Pubitemid 46971632)
35. Laakkonen P, Ruoslahti E. Selective delivery to vascular addresses: In vivo applications of cell-type-specific cell-penetrating peptides. In: Langel Ü, editor, Handbook of cell-penetrating peptides. CRC Press, Boca Raton 2007. p. 413-422
36. Myrberg H, Zhang LL, Mae M, et al. Design of a tumor-homing cell-penetrating peptide. Bioconjugate Chem 2008;19:70-75
37. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101:17867-17872 (Pubitemid 40051978)
38. Sato AK, Viswanathan M, Kent RB, et al. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006;17:638-642 (Pubitemid 44791908)
39. Gysin R, Wergedal JE, Sheng MHC, et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defects in rats. Gene Ther 2002;9:991-999 (Pubitemid 34893583)